AI Governance for Pharmaceutical Medical Information Chatbots
AI governance for pharmaceutical medical information chatbots requires runtime controls, not just model-level safeguards. This means assigning each chatbot a distinct machine identity, scoping its access to product labeling, clinical data, and adverse event systems on a least-privilege basis, enforcing policy on every tool call before execution, and generating tamper-evident audit logs sufficient to reconstruct any response for FDA OPDP or EMA-style review.
Agent Identity and Least-Privilege Access Architecture
Medical information chatbots typically need to reach several distinct data sources: approved product labeling, internal clinical or regulatory repositories, and adverse event reporting systems such as FAERS or EudraVigilance. Treating these as a single application-wide credential collapses the distinctions regulators and internal compliance teams rely on. NIST SP 800-207 Zero Trust principles support a different model: each AI agent is treated as its own identity, subject to continuous authorization checks rather than persistent broad access.
Runtime Governance Controls for Medical Information Chatbots
Agent Identity
Distinct machine identity per deployment for attribution and permissioning.
Least-Privilege Access
Scoped, per-data-source permissions rather than application-wide credentials.
Runtime Policy Enforcement
Tool calls and responses evaluated against policy before execution.
Tamper-Evident Audit Trail
Structured logs supporting regulatory reconstruction of responses.
Why Medical Information Chatbots Are a Distinct Governance Problem
Runtime Policy Enforcement for Tool Calls and Responses
Tool-Call Governance for Third-Party Integrations
The following practices govern how tool calls to external APIs and knowledge bases are validated and monitored at runtime.
| Practice | Description |
|---|---|
| Scope validation before invocation | Confirm that any external API or knowledge-base call falls within the agent's defined permission set before it executes. |
| Response content validation | Check returned content against expected format and source before it is passed into the response pipeline, independent of the LLM itself. |
| Excessive-agency testing | Test the system against attempted unauthorized API calls or unscoped data retrieval, consistent with OWASP's LLM Top 10 categories for Excessive Agency and Insecure Plugin Design. |
| Sensitive information handling | Apply access controls to any tool or source that could return protected health information or proprietary regulatory data, addressing OWASP's Sensitive Information Disclosure risk category. |
Audit and Traceability Requirements for Regulatory Review
- Each response can be reconstructed to show which sources were retrieved and which tools were invoked
- Audit records are structured and tamper-evident, not general-purpose application logs
- Prompts, retrieved sources, tool calls, and generated responses are captured as a linked record per interaction
- Logging design anticipates FDA OPDP or EMA-style review of promotional or medical information content
- Access to adverse event or pharmacovigilance systems by the AI agent is logged to the same standard applied to human user access
Evaluate Runtime Governance for Medical Information Chatbots
Governance leaders assessing or building these systems should be able to answer how agent identity, least-privilege access, tool-call policy, and audit logging are enforced at runtime, not only at the model level.
Explore Runtime Governance